We're proud to welcome Directo, an innovative pharmacy supply chain startup led by founder Gavin Upiter, to the Investible portfolio.
Today, we are pleased to share a look at the thesis behind our latest publicly-announced investment in Directo, and its ambitious founder Gavin Upiter.
Directo is an online B2B marketplace that is transforming the management and interactions of the supply chain for pharmacies in Australia, by connecting them directly with suppliers and wholesalers. The transformation is enabled by a networked marketplace built on a proprietary enterprise tech stack that is configured for, and integrates, into the pharmacy enterprise solutions.
Directo adds tremendous value, reducing costs in the supply chain, improving efficiency, ensuring price transparency and simplifying interactions between suppliers and pharmacies. In doing so, the company is establishing itself as the owner of digital pharmaceutical distribution within Australia, a multibillion-dollar market with little to no direct competition.
Investible is excited to lead this oversubscribed $2.3m seed round, which was also supported by existing investors and HNWs, mainly industry insiders. We are proud to represent the company’s first institutional investor on its cap table.
A shining example of lines over dots
We first met the Founder and CEO of Directo, Gavin Upiter, in 2019. While overwhelmingly impressed with his expertise, drive and the early traction he had achieved, our Investment Committee passed on an investment in 2019 only to reconsider the opportunity and invest two years later. Maintaining these open lines of communication with founders, even when we pass on an investment round is one of our core operating principles.
During that period, Gavin was able to address concerns regarding the company’s ability to stand-up a thriveable digital marketplace in a market which is dominated by wholesalers that often control retail buying groups. He also provided conviction over the economics of a low-margin model. Further confidence was gleaned from Gavin’s decision to speak without the aid of a PowerPoint presentation during the Investment Committee, something that we do not often see, but which resonated with those present given his compelling articulation of his vision and path to achieve all that he and his team have set out.
An incredible founder-solution fit
Gavin’s vast professional history as managing director/executive level at multiple pharmaceutical businesses could not be overlooked. His proven execution on his vision to break into a historically complex and difficult market was compelling. Very few people exhibit the level of sector knowledge—let alone hustle—that Gavin does, which is necessary to displace the traditional buying practices of pharmacies.
We believe this monumental objective can only be tackled by an industry ‘insider’ who is able to successfully navigate the fragmentation between who owns, controls and operates pharmacies. In practice, this sometimes took Gavin and his team 12 months of investment to onboard a single pharmacy. However, once a single pharmacy within a group is onboarded, the speed at which the rest of the group can be onboarded, as well as their suppliers, is undeniable.
Getting the marketplace humming
Arguably the single largest prohibiting factor to the success of a marketplace in this sector is to achieve sufficient penetration on the demand and supply side to start to be value accretive to customers. At the time of our investment, Directo had 240 pharmacies onboarded, from ~35 pharmacy groups, and 61 suppliers, with a very healthy pipeline. With users ratcheting up at a compelling pace and GMV following suit it was evident that the Directo marketplace had reached the inflection point where it was now beginning to hum.
While Gavin and the team had worked extremely hard over the last two years to build relationships with large pharmacy groups, the flywheel effects were starting to merge resulting in organic customer acquisition. This was evidenced by the number of pharmacies encouraging suppliers that they buy from, and suppliers encouraging the pharmacies they service, to join the Directo platform to unlock supply chain efficiencies. These favorable ‘network’ dynamics are expected to deliver significant organic growth into the future and provided a strong signal that it was the right time to invest.
We’re excited to be partnering with Directo as the promising young business accelerates its go-to-market strategy and grows its team to bring efficiency to a hugely underserviced sector.
The Investible group of companies includes various entities who are corporate authorised representatives (CAR) of Boutique Capital Pty Ltd (BCPL) AFSL 508011. The full list of entities are detailed below/via a link.
CAR has taken all reasonable care in producing all the information contained in the website including but not limited to reports, tables, maps, diagrams and photographs. However, CAR will not be responsible for loss or damage arising from the use of this information. The contents of this website should not be used as a substitute for detailed investigations or analysis on any issues or questions the reader wishes to have answered.
You may download the information for your own personal use or to inform others about our materials, but you may not reproduce or modify it without our express permission. To the extent to which this website contains advice it is general advice only and has been prepared by the Company for individuals identified as wholesale investors for the purposes of providing a financial product or financial service, under Section 761G or Section 761GA of the Corporations Act 2001 (Cth).
The information in this website is not intended to be relied upon as advice to investors or potential investors and has been prepared without taking into account personal investment objectives, financial circumstances or particular needs. Recipients of this information are advised to consult their own professional advisers about legal, tax, financial or other matters relevant to the suitability of this information.
Any investment(s) summarised in this website is subject to known and unknown risks, some of which are beyond the control of CAR and their directors, employees, advisers or agents. CAR does not guarantee any particular rate of return or the performance, nor does CAR and its directors personally guarantee the repayment of capital or any particular tax treatment. Past performance is not indicative of future performance.
All investments carry some level of risk, and there is typically a direct relationship between risk and return. We describe what steps we take to mitigate risk (where possible) in the investment documentation, which must be read prior to investing. It is important to note risk cannot be mitigated completely.
Whilst the contents of this website is based on information from sources which CAR considers reliable, its accuracy and completeness cannot be guaranteed. Data is not necessarily audited or independently verified. Any opinions reflect CAR’s judgment at this date and are subject to change. CAR has no obligation to provide revised assessments in the event of changed circumstances. To the extent permitted by law, BCPL, CAR and their directors and employees do not accept any liability for the results of any actions taken or not taken on the basis of information in this website, or for any negligent misstatements, errors or omissions.